Levetiracetam Tablet
Product Images NDC 70518-4306

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-4306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Levetiracetam 250 mg oral tablets, package contains 30 tablets. Label shows the brand Remedy Repack and indicates repackaging by RemedyRepack Inc., Indiana, PA. Manufacturer is Tris Pharma, Inc., Monmouth Junction, NJ. Includes bar code, QR code, and storage directions for 20-25°C (68-77°F) with permitted excursions to 15-30°C (59-86°F).*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

Chemical structure of levetiracetam, showing its molecular framework with a pyrrolidone ring, ethyl group, and amide side chain.*

FDA Label Image

Figure 1 (Levetiracetam Tablets 2)

A bar chart comparing the percentage of patients among three groups receiving placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows higher patient percentages for both Levetiracetam dosage groups compared to placebo, with values around 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

A bar chart showing the percentage of patients responding to placebo and two dosages of levetiracetam (1000 mg/day and 2000 mg/day). The y-axis represents percent of patients, with levetiracetam 2000 mg/day showing the highest response at 35.2%, followed by levetiracetam 1000 mg/day at 20.8%, and placebo at 6.3%. Sample sizes are indicated below each category.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

Bar chart comparing the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day. The chart shows 14.4% for placebo (N=104) and 39.4% for Levetiracetam (N=180), indicating patient response rates for these two groups.*

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The Y-axis represents the percentage of patients, and the X-axis labels two groups: Placebo (N=97) at 19.6% and Levetiracetam (N=101) at 44.6%, with a statistical significance marker above the Levetiracetam bar.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The chart shows about 19.6% for the placebo group and 43.1% for the Levetiracetam group, with an asterisk indicating statistical significance or notable data point for the Levetiracetam group.*

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

A vertical bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The Levetiracetam group shows a higher percentage, 72.2%, compared to 45.2% in the Placebo group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.